MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/gutjnl-2023-329923

Медицинская библиотека · Gut · 2023

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.

Juanola Adrià, Ma Ann Thu, de Wit Koos, Gananandan Kohilan, Roux Olivier, Zaccherini Giacomo, Jiménez César, Tonon Marta, Solé Cristina, Villaseca Clara, Uschner Frank E, Graupera Isabel, Pose Elisa, Moreta Maria José, Campion Daniela, Beuers Ulrich, Mookerjee Rajeshawar P, Francoz Claire, Durand Francois, Vargas Victor, Piano Salvatore, Alonso Sonia, Trebicka Jonel, Laleman Wim, Asrani Sumeet K, Soriano German, Alessandria Carlo, Serra-Burriel Miquel, Morales-Ruiz Manuel, Torres Ferran, Allegretti Andrew S, Krag Aleksander, Caraceni Paolo, Watson Hugh, Abraldes Juan G, Solà Elsa, Kamath Patrick S, Hernaez Ruben, Ginès Pere, LiverHope Investigators

МетаанализСистематический обзорСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were initially developed. Novel biomarkers have been proposed to improve prognostication accuracy and even to predict development of complications.

METHODS

We performed a systematic review and meta-analysis on novel urine and blood biomarkers and their ability to predict 90-day mortality in patients with decompensated cirrhosis. Secondary outcomes included 28-day and 1-year mortality, and development of acute-on-chronic liver failure, acute kidney injury and other complications. To overcome differences in units, temporal changes in assays and reporting heterogeneity, we used the ratio of means (RoM) as measure of association for assessing strength in predicting outcomes. An RoM>1 implies that the mean biomarker level is higher in those that develop the outcome than in those that do not.

RESULTS

Of 6629 unique references, 103 were included, reporting on 29 different biomarkers, with a total of 31 362 biomarker patients. Most studies were prospective cohorts of hospitalised patients (median Child-Pugh-Turcotte score of 9 and MELD score of 18). The pooled 90-day mortality rate was 0.27 (95% CI 0.24 to 0.29). The RoM for predicting 90-day mortality was highest for interleukin 6 (IL-6) (2.56, 95% CI 2.39 to 2.74), followed by urinary neutrophil gelatinase-associated lipocalin (uNGAL) (2.42, 95% CI 2.20 to 2.66) and copeptin (2.33, 95% CI 2.17 to 2.50). These RoMs were all higher than for MELD (1.44, 95% CI 1.42 to 1.46).

CONCLUSION

Novel biomarkers, including IL-6, uNGAL and copeptin, can probably improve prognostication of patients with decompensated cirrhosis compared with MELD alone.

Для цитирования: Juanola Adrià, Ma Ann Thu, de Wit Koos, Gananandan Kohilan, Roux Olivier, Zaccherini Giacomo, Jiménez César, Tonon Marta, Solé Cristina, Villaseca Clara, Uschner Frank E, Graupera Isabel, Pose Elisa, Moreta Maria José, Campion Daniela, Beuers Ulrich, Mookerjee Rajeshawar P, Francoz Claire, Durand Francois, Vargas Victor, Piano Salvatore, Alonso Sonia, Trebicka Jonel, Laleman Wim, Asrani Sumeet K, Soriano German, Alessandria Carlo, Serra-Burriel Miquel, Morales-Ruiz Manuel, Torres Ferran, Allegretti Andrew S, Krag Aleksander, Caraceni Paolo, Watson Hugh, Abraldes Juan G, Solà Elsa, Kamath Patrick S, Hernaez Ruben, Ginès Pere, LiverHope Investigators. Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.. Gut. 2023. DOI: 10.1136/gutjnl-2023-329923.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.